was associated with induction of T-cell immunity against viral antigens and reduction of hepatic expression of Foxp3. Studies performed to elucidate the rational behind the lack of antiviral activity of IL-12 in animals with high viremia showed that the presence of high amounts of WHV-DNA in serum is associated with the absence of IL-12-responsiveness in vitro. In conclusion, IL-12-based gene therapy is an efficient approach to treat chronic hepadnavirus infection in all cases with viral load below 10 10 vg/ml, which is the situation of most patients with chronic hepatitis B. The elucidation of the precise mechanisms responsible for the lack of response to IL-12 in animals with high viral load will be important for the development of more efficient therapies against chronic hepatitis infection. + T-cell function, promote disease progression and represent both a potential prognostic marker and a therapeutic target for HBV-related HCC individuals.
